Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
14 May 2024 - 10:00PM
Business Wire
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present
data from its oncology pipeline and product portfolio at the 60th
Annual Meeting of the American Society of Clinical Oncology (ASCO)
being held May 31-June 4, 2024, in Chicago, Ill.
Takeda’s presentations will span across a range of cancers,
including colorectal, lung, lymphoma, multiple myeloma and leukemia
and feature both clinical and real-world data generated to optimize
treatment approaches and inform patient care.
“At Takeda Oncology, we’re committed to addressing the areas of
highest patient need while leveraging our expertise in key disease
areas, including colorectal cancer, lung cancer and hematological
malignancies,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the
Oncology Therapeutic Area Unit (OTAU) at Takeda. “Our presentations
at ASCO, including data being presented in Hodgkin lymphoma and
colorectal cancer, highlight the importance of combining our
internal innovation with external partnerships to introduce new
solutions and benefit the lives of people with cancer.”
A full list of company-sponsored abstracts can be found
here.
Takeda’s Commitment to Oncology At Takeda Oncology, we
are united by our aspiration to cure cancer and motivated every day
to work harder for patients with limited or ineffective treatment
options. Our agile structure and deep in-house expertise are
complemented by a network of partnerships that optimize our ability
to research, develop and deliver transformative medicines to people
living with cancer. Building on decades of leadership in oncology,
we are focused on providing approved medicines for patients in need
and advancing a cutting-edge oncology pipeline with the potential
to introduce new therapies for people with solid tumors and
hematologic cancers. With inspiration from patients and innovation
from everywhere, we are committed to outsmarting cancer so that
more patients can benefit from – and have access to – innovative
medicines. For more information, visit www.takedaoncology.com.
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral
briefing and any question-and-answer in connection with it) is not
intended to, and does not constitute, represent or form part of any
offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws. The companies in which
Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for
convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our”
are also used to refer to subsidiaries in general or to those who
work for them. These expressions are also used where no useful
purpose is served by identifying the particular company or
companies.
Forward-Looking Statements This press release and any
materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could” “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those expressed or implied
by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic
conditions in Japan and the United States; competitive pressures
and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in
countries in which Takeda operates, or on other facets of its
business; the timing and impact of post-merger integration efforts
with acquired companies; the ability to divest assets that are not
core to Takeda’s operations and the timing of any such
divestment(s); and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with
the U.S. Securities and Exchange Commission, available on Takeda’s
website at: https://www.takeda.com/investors/sec-filings/ or at
www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
Medical Information This press release contains
information about products that may not be available in all
countries, or may be available under different trademarks, for
different indications, in different dosages, or in different
strengths. Nothing contained herein should be considered a
solicitation, promotion or advertisement for any prescription drugs
including the ones under development.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514635691/en/
Japanese Media Jun Saito jun.saito@takeda.com
U.S. and International Media Sara Noonan
sara.noonan@takeda.com
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Sep 2023 to Sep 2024